Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi

doi:10.1016/s0140-6736(09)61259-9

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

G Comi
, V Martinelli
, M Rodegher
, L Moiola
, O Bajenaru
, A Carra
, I Elovaara
, F Fazekas
, H Hartung
, J Hillert
, J King
, S Komoly
, C Lubetzki
, X Montalban
, K Myhr
, M Ravnborg
, P Rieckmann
, D Wynn
, C Young
, M Filippi

Research output: Contribution to journal › Article › Scientific › peer-review

549 Citations (Scopus)

Original language	English
Pages (from-to)	1503-1511
Journal	The Lancet
Volume	374
Issue number	9700
DOIs	https://doi.org/10.1016/s0140-6736(09)61259-9
Publication status	Published - 2009
Publication type	A1 Journal article-refereed

Access to Document

10.1016/s0140-6736(09)61259-9

Cite this

Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., King, J., Komoly, S., Lubetzki, C., Montalban, X., Myhr, K., Ravnborg, M., Rieckmann, P., Wynn, D., Young, C., & Filippi, M. (2009). Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. The Lancet, 374(9700), 1503-1511. https://doi.org/10.1016/s0140-6736(09)61259-9

@article{1247ceedd2404a20baaf10eab72d8132,

title = "Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial",

author = "G Comi and V Martinelli and M Rodegher and L Moiola and O Bajenaru and A Carra and I Elovaara and F Fazekas and H Hartung and J Hillert and J King and S Komoly and C Lubetzki and X Montalban and K Myhr and M Ravnborg and P Rieckmann and D Wynn and C Young and M Filippi",

year = "2009",

doi = "10.1016/s0140-6736(09)61259-9",

language = "English",

volume = "374",

pages = "1503--1511",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "9700",

}

Comi, G, Martinelli, V, Rodegher, M, Moiola, L, Bajenaru, O, Carra, A, Elovaara, I, Fazekas, F, Hartung, H, Hillert, J, King, J, Komoly, S, Lubetzki, C, Montalban, X, Myhr, K, Ravnborg, M, Rieckmann, P, Wynn, D, Young, C & Filippi, M 2009, 'Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial', The Lancet, vol. 374, no. 9700, pp. 1503-1511. https://doi.org/10.1016/s0140-6736(09)61259-9

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. / Comi, G; Martinelli, V; Rodegher, M et al.
In: The Lancet, Vol. 374, No. 9700, 2009, p. 1503-1511.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

AU - Comi, G

AU - Martinelli, V

AU - Rodegher, M

AU - Moiola, L

AU - Bajenaru, O

AU - Carra, A

AU - Elovaara, I

AU - Fazekas, F

AU - Hartung, H

AU - Hillert, J

AU - King, J

AU - Komoly, S

AU - Lubetzki, C

AU - Montalban, X

AU - Myhr, K

AU - Ravnborg, M

AU - Rieckmann, P

AU - Wynn, D

AU - Young, C

AU - Filippi, M

PY - 2009

Y1 - 2009

U2 - 10.1016/s0140-6736(09)61259-9

DO - 10.1016/s0140-6736(09)61259-9

M3 - Article

SN - 0140-6736

VL - 374

SP - 1503

EP - 1511

JO - The Lancet

JF - The Lancet

IS - 9700

ER -